Results 211 to 220 of about 126,339 (259)
Some of the next articles are maybe not open access.
EGCG as Anti-Obesity and Anticancer Agent
2021EGCG, the most abundant catechins of green tea exhibits several beneficial impacts on human health and helps in the amelioration of various pathological conditions including cardiovascular diseases, obesity, and cancer. The anti-obesity potential of EGCG depends on its potent antioxidant property, lipid metabolism modulatory action, and adipogenesis ...
Shiv Govind Rawat +5 more
openaire +1 more source
Serotonergic Anti-Obesity Agents
Drugs, 2011The role of serotonin (5-hydroxytryptamine) in appetite control is long established. Serotonergic manipulations reduce food intake in rodents in a manner consistent with satiety. In humans, drugs such as fenfluramine, dexfenfluramine and sibutramine all reduce energy intake, suppress hunger and enhance satiety.
Jason C G, Halford +4 more
openaire +2 more sources
Studies on fenfluramhe as an anti-obesity agent
Current Medical Research and Opinion, 1979SummaryThe results of three studies on the use of fenfluramine in patients with refractory obesity are reviewed. The mean weight loss achieved on continuous therapy compared favourably with that recorded in other studies in similar patients receiving other anorectic agents. It was evident, however, that although all patients on fenfluramine lost weight
P. G. Preston, M. J. Ford, J. F. Munro
openaire +1 more source
Anti-Obesity Agents and the US Food and Drug Administration
Current Obesity Reports, 2014Despite the growing market for obesity care, the US Food and Drug Administration (FDA) has approved only two new pharmaceutical agents-lorcaserin and combination phentermine/topiramate-for weight reduction since 2000, while removing three agents from the market in the same time period. This article explores the FDA's history and role in the approval of
exaly +3 more sources
Synthesis of a potential anti-obesity agent
1995This chapter examines ICI D7114, which was developed as a possible treatment for obesity and non-insulin dependent diabetes. It looks at animal studies that showed how ICI D7114 acts by stimulating β3-receptors in brown fat tissue and leads to an increase in resting the metabolic rate.
Stan Lee, Graham Robinson
openaire +1 more source
Diacylglycerol: Efficacy and Mechanism of Action of an Anti‐Obesity Agent
Obesity Research, 2005AbstractObesity is at the forefront of global health issues and directly contributes to many chronic illnesses. Several dietary components show promise in the treatment of obesity, one of which is oil rich in diacylglycerols (DAGs). Present objectives are to examine scientific knowledge concerning DAG to assess evidence supporting the effects on ...
Iwona, Rudkowska +5 more
openaire +2 more sources
Centrally Acting Anti-Obesity Agents
2006Publisher Summary This chapter discusses agents that target central pathways involved in controlling food intake, body weight, and reward and that are under active investigation. Only two drugs are currently approved for chronic weight loss treatment—a pancreatic lipase inhibitor called orlistat (Xenical ® ) and a monoamine reuptake inhibitor ...
David Hepworth +2 more
openaire +1 more source
Nomilin as an Anti-Obesity and Anti-Hyperglycemic Agent
2013Recent scientific findings support the notion that bile acids, which are cholesterol catabolites, are bioactive signaling molecules that function as ligands for the farnesoid X receptor or a G-protein-coupled receptor, TGR5. Through these receptors, bile acids can maintain not only bile acid homeostasis but also lipid and carbohydrate homeostasis.
openaire +2 more sources